IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS

Irritable Bowel Syndrome Treatment Market, by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and Others), by Medical Condition (IBS-constipation and IBS-diarrhea), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jun 2022
Code : CMI506
Pages :156
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

Global Irritable Bowel Syndrome Treatment Market: Key Developments

In April 2022, Ardelyx, a biopharmaceutical company, announced the launch of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first U.S. Food and Drug Administration approved product for Ardelyx.

In March 2022, Indegene, a technology-led healthcare solutions provider, and metaMe Health, a Prescription Digital Therapeutics (PDT) company and developer of Regulora, partnered to bring Regulora to market for the treatment of abdominal pain due to Irritable Bowel Syndrome (IBS).